News
- Author:
- Heidi Splete
Publish date: November 29, 2023
To support clinicians in diagnosing and managing DRESS, a steering committee conducted a literature review to examine current research, identify ev...
News
- Author:
- Heidi Splete
Publish date: November 29, 2023
Safety and effectiveness of a bedaquiline, pretomanid, and linezolid combination supports its use as a first-line treatment for adolescents and adu...
News
- Author:
- Heidi Splete
Publish date: November 28, 2023
Study provides more data on the safety of aspirin use during pregnancy in patients with IBD.
News
- Author:
- Heidi Splete
Publish date: November 28, 2023
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
News
- Author:
- Heidi Splete
Publish date: November 27, 2023
A knowledge summary from the World Health Organization also emphasizes the need for control measures to protect youth from tobacco marketing.
News
- Author:
- Heidi Splete
Publish date: November 17, 2023
Lebrikizumab remains under review in the United States.
News
- Author:
- Heidi Splete
Publish date: November 17, 2023
Risk was highest among bipolar disorder patients who received long-term treatment with valproate.
News
- Author:
- Heidi Splete
Publish date: November 17, 2023
Implementation of a standard algorithm also improved neonatal status based on Apgar scores.
News
- Author:
- Heidi Splete
Publish date: November 16, 2023
Lungs ravaged by disease and infection were removed, and breast implants used to hold heart in place while awaiting transplant.
News
- Author:
- Heidi Splete
Publish date: November 16, 2023
AMA and ACEP support proposed changes that would affect workforce hiring and working conditions for physicians.
News
- Author:
- Heidi Splete
Publish date: November 14, 2023
AKs have been associated with a small risk for cutaneous SCC, but associations with risk for other skin cancers have not been well studied.
News
- Author:
- Heidi Splete
Publish date: November 13, 2023
A post hoc analysis of the NOBILITY trial showed improved outcomes for patients taking obinutuzumab (Gazyva), compared with placebo.
News
- Author:
- Heidi Splete
Publish date: November 13, 2023
Results from a pilot study examining a shortened prednisone taper of 8 weeks’ length rather than 26 weeks suggest it may be possible to reduce pati...
News
- Author:
- Heidi Splete
Publish date: November 9, 2023
Acne has been reported to be an adverse effect of JAK inhibitors, but not much is known about how common acne is overall.
News
- Author:
- Heidi Splete
Publish date: November 7, 2023
A Clinical Practice Update from the AGA addresses concerns over delayed gastric emptying and aspiration during sedation.
